Recent Advances in Alzheimer’s Disease Treatments with Therapeutic Antibodies to Amyloid-β
DOI:
https://doi.org/10.47611/jsrhs.v11i3.3453Keywords:
Alzheimer’s Disease, Therapeutic Antibodies, Amyloid-β, AducanumabAbstract
Alzheimer's disease (AD) is one of the most prevalent and devastating neurodegenerative disorders which affects tens of millions of patients. It imposes significant physical, emotional, and financial burdens on patients, families, and society. Formation of Amyloid-β (Aβ) plaques from the accumulation of Aβ peptides in the cortex and hippocampal region is considered one of the fundamental neuropathological pillars of the disease. Pathological Aβ peptides are generated from its precursor protein through proteolysis. Four small molecule medications were approved by the U. S. Food and Drug Administration (FDA) since 1968 to treat the cognitive symptoms of AD, but they are not curative and have no effect on the development of AD. At least four anti-Aβ antibodies and dozens of other anti-Aβ small molecule agents have been evaluated in clinical trials in the past decades but none of them showed consistent clinical efficacy, presumably because they cannot remove Aβ plaques effectively enough or other reasons such as the patient selection and trial design. Despite the failures, more anti-Aβ antibodies are under development, aiming for more efficient Aβ plaques removal through selectively targeting Aβ oligomers. Among those aducanumab was approved by FDA in 2021 as the first drug to address the underlying biology of AD rather than the symptoms.
Downloads
References or Bibliography
Adair, J. R., Athwal, D. S., Bodmer, M. W., Bright, S. M., Collins, A. M., Pulito, V. L., Rao, P. E., Reedman, R., Rothermel, A. L., Xu, D., & et al. (1994). Humanization of the murine anti-human CD3 monoclonal antibody OKT3. Hum Antibodies Hybridomas, 5(1-2), 41-47. https://doi.org/10.3233/HAB-1994-51-206
Alzheimer's Association. (2022). 2022 Alzheimer's disease facts and figures. Alzheimers Dement, 18(4), 700-789. https://doi.org/10.1002/alz.12638
Armstrong, R. A. (2019). Risk factors for Alzheimer's disease. Folia Neuropathol, 57(2), 87-105. https://doi.org/10.5114/fn.2019.85929
Bekris, L. M., Yu, C. E., Bird, T. D., & Tsuang, D. W. (2010). Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol, 23(4), 213-227. https://doi.org/10.1177/0891988710383571
Bohrmann, B., Baumann, K., Benz, J., Gerber, F., Huber, W., Knoflach, F., Messer, J., Oroszlan, K., Rauchenberger, R., Richter, W. F., Rothe, C., Urban, M., Bardroff, M., Winter, M., Nordstedt, C., & Loetscher, H. (2012). Gantenerumab: a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. J Alzheimers Dis, 28(1), 49-69. https://doi.org/10.3233/JAD-2011-110977
Breijyeh, Z., & Karaman, R. (2020). Comprehensive Review on Alzheimer's Disease: Causes and Treatment. Molecules, 25(24). https://doi.org/10.3390/molecules25245789
Bressler, S. L., Gray, M. D., Sopher, B. L., Hu, Q., Hearn, M. G., Pham, D. G., Dinulos, M. B., Fukuchi, K., Sisodia, S. S., Miller, M. A., Disteche, C. M., & Martin, G. M. (1996). cDNA cloning and chromosome mapping of the human Fe65 gene: interaction of the conserved cytoplasmic domains of the human beta-amyloid precursor protein and its homologues with the mouse Fe65 protein. Hum Mol Genet, 5(10), 1589-1598. https://doi.org/10.1093/hmg/5.10.1589
Buss, N. A., Henderson, S. J., McFarlane, M., Shenton, J. M., & de Haan, L. (2012). Monoclonal antibody therapeutics: history and future. Curr Opin Pharmacol, 12(5), 615-622. https://doi.org/10.1016/j.coph.2012.08.001
Cehlar, O., Skrabana, R., Revajova, V., & Novak, M. (2018). Structural aspects of Alzheimer's disease immunotherapy targeted against amyloid-beta peptide. Bratisl Lek Listy, 119(4), 201-204. https://doi.org/10.4149/BLL_2018_037
Chin, A. L., Negash, S., & Hamilton, R. (2011). Diversity and disparity in dementia: the impact of ethnoracial differences in Alzheimer disease. Alzheimer Dis Assoc Disord, 25(3), 187-195. https://doi.org/10.1097/WAD.0b013e318211c6c9
Cipriani, G., Dolciotti, C., Picchi, L., & Bonuccelli, U. (2011). Alzheimer and his disease: a brief history. Neurol Sci, 32(2), 275-279. https://doi.org/10.1007/s10072-010-0454-7
Cras, P., Kawai, M., Lowery, D., Gonzalez-DeWhitt, P., Greenberg, B., & Perry, G. (1991). Senile plaque neurites in Alzheimer disease accumulate amyloid precursor protein. Proc Natl Acad Sci U S A, 88(17), 7552-7556. https://doi.org/10.1073/pnas.88.17.7552
Cummings, J., Aisen, P., Lemere, C., Atri, A., Sabbagh, M., & Salloway, S. (2021). Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. Alzheimers Res Ther, 13(1), 98. https://doi.org/10.1186/s13195-021-00838-z
Delpak, A., & Talebi, M. (2020). On the impact of age, gender and educational level on cognitive function in Alzheimer's disease: A quantitative approach. Arch Gerontol Geriatr, 89, 104090. https://doi.org/10.1016/j.archger.2020.104090
Demattos, R. B., Lu, J., Tang, Y., Racke, M. M., Delong, C. A., Tzaferis, J. A., Hole, J. T., Forster, B. M., McDonnell, P. C., Liu, F., Kinley, R. D., Jordan, W. H., & Hutton, M. L. (2012). A plaque-specific antibody clears existing beta-amyloid plaques in Alzheimer's disease mice. Neuron, 76(5), 908-920. https://doi.org/10.1016/j.neuron.2012.10.029
DeTure, M. A., & Dickson, D. W. (2019). The neuropathological diagnosis of Alzheimer's disease. Mol Neurodegener, 14(1), 32. https://doi.org/10.1186/s13024-019-0333-5
Doran, E., Keator, D., Head, E., Phelan, M. J., Kim, R., Totoiu, M., Barrio, J. R., Small, G. W., Potkin, S. G., & Lott, I. T. (2017). Down Syndrome, Partial Trisomy 21, and Absence of Alzheimer's Disease: The Role of APP. J Alzheimers Dis, 56(2), 459-470. https://doi.org/10.3233/JAD-160836
Esmail, S., & Danter, W. R. (2021). NEUBOrg: Artificially Induced Pluripotent Stem Cell-Derived Brain Organoid to Model and Study Genetics of Alzheimer's Disease Progression. Front Aging Neurosci, 13, 643889. https://doi.org/10.3389/fnagi.2021.643889
Fernandez, M. A., Klutkowski, J. A., Freret, T., & Wolfe, M. S. (2014). Alzheimer presenilin-1 mutations dramatically reduce trimming of long amyloid beta-peptides (Abeta) by gamma-secretase to increase 42-to-40-residue Abeta. J Biol Chem, 289(45), 31043-31052. https://doi.org/10.1074/jbc.M114.581165
Fink, H. A., Linskens, E. J., MacDonald, R., Silverman, P. C., McCarten, J. R., Talley, K. M. C., Forte, M. L., Desai, P. J., Nelson, V. A., Miller, M. A., Hemmy, L. S., Brasure, M., Taylor, B. C., Ng, W., Ouellette, J. M., Sheets, K. M., Wilt, T. J., & Butler, M. (2020). Benefits and Harms of Prescription Drugs and Supplements for Treatment of Clinical Alzheimer-Type Dementia. Ann Intern Med, 172(10), 656-668. https://doi.org/10.7326/M19-3887
Fleisher, A. S., Lowe, S. L., Liu, P., Shcherbinin, S., Li, L., Chua, L., Nakano, M., Hawdon, A., Willis, B. A., Schwarz, A. J., Demattos, R. B., Mintun, M. A., & Irizarry, M. C. (2006). O1‐09‐01: Significant and Sustained Florbetapir F18 Uptake Reduction in Patients with Symptomatic Alzheimer's Disease with Ly3002813, a β‐Amyloid Plaque‐Specific Antibody. Alzheimer's & Dementia, 14(7S_Part_4). https://doi.org/10.1016/j.jalz.2018.06.2378
Folch, J., Ettcheto, M., Petrov, D., Abad, S., Pedros, I., Marin, M., Olloquequi, J., & Camins, A. (2018). Review of the advances in treatment for Alzheimer disease: Strategies for combating beta-amyloid protein. Neurologia (Engl Ed), 33(1), 47-58. https://doi.org/10.1016/j.nrl.2015.03.012
Goure, W. F., Krafft, G. A., Jerecic, J., & Hefti, F. (2014). Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics. Alzheimers Res Ther, 6(4), 42. https://doi.org/10.1186/alzrt272
Haddad, H. W., Malone, G. W., Comardelle, N. J., Degueure, A. E., Poliwoda, S., Kaye, R. J., Murnane, K. S., Kaye, A. M., & Kaye, A. D. (2022). Aduhelm, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer's Disease: A comprehensive review. Health Psychol Res, 10(3), 37023. https://doi.org/10.52965/001c.37023
Hersi, M., Irvine, B., Gupta, P., Gomes, J., Birkett, N., & Krewski, D. (2017). Risk factors associated with the onset and progression of Alzheimer's disease: A systematic review of the evidence. Neurotoxicology, 61, 143-187. https://doi.org/10.1016/j.neuro.2017.03.006
Hippius, H., & Neundörfer, G. (2022). The discovery of Alzheimer's disease. Dialogues in Clinical Neuroscience, 5(1), 101-108. https://doi.org/10.31887/DCNS.2003.5.1/hhippius
Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., Case, M., Dean, R. A., Hake, A., Sundell, K., Poole Hoffmann, V., Carlson, C., Khanna, R., Mintun, M., DeMattos, R., Selzler, K. J., & Siemers, E. (2018). Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease. N Engl J Med, 378(4), 321-330. https://doi.org/10.1056/NEJMoa1705971
Horder, H., Johansson, L., Guo, X., Grimby, G., Kern, S., Ostling, S., & Skoog, I. (2018). Midlife cardiovascular fitness and dementia: A 44-year longitudinal population study in women. Neurology, 90(15), e1298-e1305. https://doi.org/10.1212/WNL.0000000000005290
Husna Ibrahim, N., Yahaya, M. F., Mohamed, W., Teoh, S. L., Hui, C. K., & Kumar, J. (2020). Pharmacotherapy of Alzheimer's Disease: Seeking Clarity in a Time of Uncertainty. Front Pharmacol, 11, 261. https://doi.org/10.3389/fphar.2020.00261
Ivanoiu, A., Pariente, J., Booth, K., Lobello, K., Luscan, G., Hua, L., Lucas, P., Styren, S., Yang, L., Li, D., Black, R. S., Brashear, H. R., & McRae, T. (2016). Long-term safety and tolerability of bapineuzumab in patients with Alzheimer's disease in two phase 3 extension studies. Alzheimers Res Ther, 8(1), 24. https://doi.org/10.1186/s13195-016-0193-y
Jeremic, D., Jimenez-Diaz, L., & Navarro-Lopez, J. D. (2021). Past, present and future of therapeutic strategies against amyloid-beta peptides in Alzheimer's disease: a systematic review. Ageing Res Rev, 72, 101496. https://doi.org/10.1016/j.arr.2021.101496
Karran, E., & De Strooper, B. (2022). The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nat Rev Drug Discov, 21(4), 306-318. https://doi.org/10.1038/s41573-022-00391-w
Ketter, N., Brashear, H. R., Bogert, J., Di, J., Miaux, Y., Gass, A., Purcell, D. D., Barkhof, F., & Arrighi, H. M. (2017). Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients. J Alzheimers Dis, 57(2), 557-573. https://doi.org/10.3233/JAD-160216
Kinoshita, A., Whelan, C. M., Smith, C. J., Berezovska, O., & Hyman, B. T. (2002). Direct visualization of the gamma secretase-generated carboxyl-terminal domain of the amyloid precursor protein: association with Fe65 and translocation to the nucleus. J Neurochem, 82(4), 839-847. https://doi.org/10.1046/j.1471-4159.2002.01016.x
Kwak, K. A., Lee, S. P., Yang, J. Y., & Park, Y. S. (2018). Current Perspectives regarding Stem Cell-Based Therapy for Alzheimer's Disease. Stem Cells Int, 2018, 6392986. https://doi.org/10.1155/2018/6392986
Kwan, P., Konno, H., Chan, K. Y., & Baum, L. (2020). Rationale for the development of an Alzheimer's disease vaccine. Hum Vaccin Immunother, 16(3), 645-653. https://doi.org/10.1080/21645515.2019.1665453
Lautenschlager, N. T., Cox, K. L., Flicker, L., Foster, J. K., van Bockxmeer, F. M., Xiao, J., Greenop, K. R., & Almeida, O. P. (2008). Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA, 300(9), 1027-1037. https://doi.org/10.1001/jama.300.9.1027
Lesne, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006). A specific amyloid-beta protein assembly in the brain impairs memory. Nature, 440(7082), 352-357. https://doi.org/10.1038/nature04533
Li, Z., Shue, F., Zhao, N., Shinohara, M., & Bu, G. (2020). APOE2: protective mechanism and therapeutic implications for Alzheimer's disease. Mol Neurodegener, 15(1), 63. https://doi.org/10.1186/s13024-020-00413-4
Liu, E., Schmidt, M. E., Margolin, R., Sperling, R., Koeppe, R., Mason, N. S., Klunk, W. E., Mathis, C. A., Salloway, S., Fox, N. C., Hill, D. L., Les, A. S., Collins, P., Gregg, K. M., Di, J., Lu, Y., Tudor, I. C., Wyman, B. T., Booth, K., Broome, S., Yuen, E., Grundman, M., Brashear, H. R., Bapineuzumab, & Clinical Trial, I. (2015). Amyloid-beta 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. Neurology, 85(8), 692-700. https://doi.org/10.1212/WNL.0000000000001877
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., Costafreda, S. G., Dias, A., Fox, N., Gitlin, L. N., Howard, R., Kales, H. C., Kivimäki, M., Larson, E. B., Ogunniyi, A., Orgeta, V., Ritchie, K., Rockwood, K., Sampson, E. L., Samus, Q., Schneider, L. S., Selbæk, G., Teri, L., & Mukadam, N. (2020). Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. The Lancet, 396(10248), 413-446. https://doi.org/10.1016/s0140-6736(20)30367-6
Logovinsky, V., Satlin, A., Lai, R., Swanson, C., Kaplow, J., Osswald, G., Basun, H., & Lannfelt, L. (2016). Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Abeta antibody. Alzheimers Res Ther, 8(1), 14. https://doi.org/10.1186/s13195-016-0181-2
Mantile, F., & Prisco, A. (2020). Vaccination against beta-Amyloid as a Strategy for the Prevention of Alzheimer's Disease. Biology (Basel), 9(12). https://doi.org/10.3390/biology9120425
Mayeux, R., & Stern, Y. (2012). Epidemiology of Alzheimer disease. Cold Spring Harb Perspect Med, 2(8). https://doi.org/10.1101/cshperspect.a006239
Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., Apostolova, L. G., Salloway, S. P., & Skovronsky, D. M. (2021). Donanemab in Early Alzheimer's Disease. N Engl J Med, 384(18), 1691-1704. https://doi.org/10.1056/NEJMoa2100708
Miyoshi, I., Fujimoto, Y., Yamada, M., Abe, S., Zhao, Q., Cronenberger, C., Togo, K., Ishibashi, T., Bednar, M. M., Kupiec, J. W., & Binneman, B. (2013). Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimer's disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study. Int J Clin Pharmacol Ther, 51(12), 911-923. https://doi.org/10.5414/CP201816
Mucke, L., & Selkoe, D. J. (2012). Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med, 2(7), a006338. https://doi.org/10.1101/cshperspect.a006338
Musiek, E. S., & Bennett, D. A. (2021). Aducanumab and the "post-amyloid" era of Alzheimer research? Neuron, 109(19), 3045-3047. https://doi.org/10.1016/j.neuron.2021.09.007
Nelson, P. T., Head, E., Schmitt, F. A., Davis, P. R., Neltner, J. H., Jicha, G. A., Abner, E. L., Smith, C. D., Van Eldik, L. J., Kryscio, R. J., & Scheff, S. W. (2011). Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies. Acta Neuropathol, 121(5), 571-587. https://doi.org/10.1007/s00401-011-0826-y
Ostrowitzki, S., Lasser, R. A., Dorflinger, E., Scheltens, P., Barkhof, F., Nikolcheva, T., Ashford, E., Retout, S., Hofmann, C., Delmar, P., Klein, G., Andjelkovic, M., Dubois, B., Boada, M., Blennow, K., Santarelli, L., Fontoura, P., & Investigators, S. C. R. (2017). A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease. Alzheimers Res Ther, 9(1), 95. https://doi.org/10.1186/s13195-017-0318-y
Panza, F., Lozupone, M., Logroscino, G., & Imbimbo, B. P. (2019). A critical appraisal of amyloid-beta-targeting therapies for Alzheimer disease. Nat Rev Neurol, 15(2), 73-88. https://doi.org/10.1038/s41582-018-0116-6
Penney, J., Ralvenius, W. T., & Tsai, L. H. (2020). Modeling Alzheimer's disease with iPSC-derived brain cells. Mol Psychiatry, 25(1), 148-167. https://doi.org/10.1038/s41380-019-0468-3
Piller, C. (2022). Blots on a field? Science, 377(6604), 358-363. https://doi.org/10.1126/science.add9993
Plotkin, S. S., & Cashman, N. R. (2020). Passive immunotherapies targeting Abeta and tau in Alzheimer's disease. Neurobiol Dis, 144, 105010. https://doi.org/10.1016/j.nbd.2020.105010
Rajan, K. B., Weuve, J., Barnes, L. L., McAninch, E. A., Wilson, R. S., & Evans, D. A. (2021). Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020-2060). Alzheimers Dement, 17(12), 1966-1975. https://doi.org/10.1002/alz.12362
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., Reichert, M., Ketter, N., Nejadnik, B., Guenzler, V., Miloslavsky, M., Wang, D., Lu, Y., Lull, J., Tudor, I. C., Liu, E., Grundman, M., Yuen, E., Black, R., Brashear, H. R., Bapineuzumab, & Clinical Trial, I. (2014). Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med, 370(4), 322-333. https://doi.org/10.1056/NEJMoa1304839
Salwa, & Kumar, L. (2021). Engrafted stem cell therapy for Alzheimer's disease: A promising treatment strategy with clinical outcome. J Control Release, 338, 837-857. https://doi.org/10.1016/j.jconrel.2021.09.007
Scarmeas, N., Luchsinger, J. A., Schupf, N., Brickman, A. M., Cosentino, S., Tang, M. X., & Stern, Y. (2009). Physical activity, diet, and risk of Alzheimer disease. JAMA, 302(6), 627-637. https://doi.org/10.1001/jama.2009.1144
Se Thoe, E., Fauzi, A., Tang, Y. Q., Chamyuang, S., & Chia, A. Y. Y. (2021). A review on advances of treatment modalities for Alzheimer's disease. Life Sci, 276, 119129. https://doi.org/10.1016/j.lfs.2021.119129
Selkoe, D. J., & Hardy, J. (2016). The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med, 8(6), 595-608. https://doi.org/10.15252/emmm.201606210
Sengupta, U., Nilson, A. N., & Kayed, R. (2016). The Role of Amyloid-beta Oligomers in Toxicity, Propagation, and Immunotherapy. EBioMedicine, 6, 42-49. https://doi.org/10.1016/j.ebiom.2016.03.035
Serrano-Pozo, A., Das, S., & Hyman, B. T. (2021). APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches. The Lancet Neurology, 20(1), 68-80. https://doi.org/10.1016/s1474-4422(20)30412-9
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011). Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med, 1(1), a006189. https://doi.org/10.1101/cshperspect.a006189
Sevigny, J., Chiao, P., Bussiere, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., O'Gorman, J., Qian, F., Arastu, M., Li, M., Chollate, S., Brennan, M. S., Quintero-Monzon, O., Scannevin, R. H., Arnold, H. M., Engber, T., Rhodes, K., Ferrero, J., Hang, Y., Mikulskis, A., Grimm, J., Hock, C., Nitsch, R. M., & Sandrock, A. (2016). The antibody aducanumab reduces Abeta plaques in Alzheimer's disease. Nature, 537(7618), 50-56. https://doi.org/10.1038/nature19323
Silva, M. V. F., Loures, C. M. G., Alves, L. C. V., de Souza, L. C., Borges, K. B. G., & Carvalho, M. D. G. (2019). Alzheimer's disease: risk factors and potentially protective measures. J Biomed Sci, 26(1), 33. https://doi.org/10.1186/s12929-019-0524-y
Singh, S., Kumar, N. K., Dwiwedi, P., Charan, J., Kaur, R., Sidhu, P., & Chugh, V. K. (2018). Monoclonal Antibodies: A Review. Curr Clin Pharmacol, 13(2), 85-99. https://doi.org/10.2174/1574884712666170809124728
Spires-Jones, T. L., & Hyman, B. T. (2014). The intersection of amyloid beta and tau at synapses in Alzheimer's disease. Neuron, 82(4), 756-771. https://doi.org/10.1016/j.neuron.2014.05.004
Steinbrook, R. (2021). The Accelerated Approval of Aducanumab for Treatment of Patients With Alzheimer Disease. JAMA Intern Med, 181(10), 1281. https://doi.org/10.1001/jamainternmed.2021.4622
Suzuki, K., Iwata, A., & Iwatsubo, T. (2017). The past, present, and future of disease-modifying therapies for Alzheimer's disease. Proc Jpn Acad Ser B Phys Biol Sci, 93(10), 757-771. https://doi.org/10.2183/pjab.93.048
Swanson, C. J., Zhang, Y., Dhadda, S., Wang, J., Kaplow, J., Lai, R. Y. K., Lannfelt, L., Bradley, H., Rabe, M., Koyama, A., Reyderman, L., Berry, D. A., Berry, S., Gordon, R., Kramer, L. D., & Cummings, J. L. (2021). A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Abeta protofibril antibody. Alzheimers Res Ther, 13(1), 80. https://doi.org/10.1186/s13195-021-00813-8
Urayama, A., Moreno-Gonzalez, I., Morales-Scheihing, D., Kharat, V., Pritzkow, S., & Soto, C. (2022). Preventive and therapeutic reduction of amyloid deposition and behavioral impairments in a model of Alzheimer's disease by whole blood exchange. Mol Psychiatry. https://doi.org/10.1038/s41380-022-01679-4
van Dyck, C. H. (2018). Anti-Amyloid-beta Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise. Biol Psychiatry, 83(4), 311-319. https://doi.org/10.1016/j.biopsych.2017.08.010
Vandenberghe, R., Rinne, J. O., Boada, M., Katayama, S., Scheltens, P., Vellas, B., Tuchman, M., Gass, A., Fiebach, J. B., Hill, D., Lobello, K., Li, D., McRae, T., Lucas, P., Evans, I., Booth, K., Luscan, G., Wyman, B. T., Hua, L., Yang, L., Brashear, H. R., Black, R. S., Bapineuzumab, & Clinical Study, I. (2016). Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials. Alzheimers Res Ther, 8(1), 18. https://doi.org/10.1186/s13195-016-0189-7
Ward, M. W., Concannon, C. G., Whyte, J., Walsh, C. M., Corley, B., & Prehn, J. H. (2010). The amyloid precursor protein intracellular domain(AICD) disrupts actin dynamics and mitochondrial bioenergetics. J Neurochem, 113(1), 275-284. https://doi.org/10.1111/j.1471-4159.2010.06615.x
Wilde, M. I., & Goa, K. L. (1996). Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Drugs, 51(5), 865-894. https://doi.org/10.2165/00003495-199651050-00010
Wiseman, F. K., Al-Janabi, T., Hardy, J., Karmiloff-Smith, A., Nizetic, D., Tybulewicz, V. L., Fisher, E. M., & Strydom, A. (2015). A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. Nat Rev Neurosci, 16(9), 564-574. https://doi.org/10.1038/nrn3983
Wolfe, M. S. (2020). Substrate recognition and processing by gamma-secretase. Biochim Biophys Acta Biomembr, 1862(1), 183016. https://doi.org/10.1016/j.bbamem.2019.07.004
Published
How to Cite
Issue
Section
Copyright (c) 2022 Jerry Yang; Aaron Bradford
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
